Hologic, Inc. (LON:0J5Q)
London · Delayed Price · Currency is GBP · Price in USD 74.98
-0.12 (-0.16%)
Dec 18, 2025, 2:49 PM BST
Hologic Revenue
In the fiscal year ending September 27, 2025, Hologic had annual revenue of $4.10B USD with 1.74% growth. Hologic had revenue of $1.05B in the quarter ending September 27, 2025, with 6.23% growth.
Revenue
$4.10B
Revenue Growth
+1.74%
P/S Ratio
4.08
Revenue / Employee
$579.99K
Employees
7,070
Market Cap
12.47B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 27, 2025 | 4.10B | 70.20M | 1.74% |
| Sep 28, 2024 | 4.03B | -100.00K | - |
| Sep 30, 2023 | 4.03B | -832.40M | -17.12% |
| Sep 24, 2022 | 4.86B | -769.50M | -13.66% |
| Sep 25, 2021 | 5.63B | 1.86B | 49.14% |
| Sep 26, 2020 | 3.78B | 409.10M | 12.15% |
| Sep 28, 2019 | 3.37B | 149.40M | 4.64% |
| Sep 29, 2018 | 3.22B | 159.10M | 5.20% |
| Sep 30, 2017 | 3.06B | 226.10M | 7.98% |
| Sep 24, 2016 | 2.83B | 127.70M | 4.72% |
| Sep 26, 2015 | 2.71B | 174.30M | 6.89% |
| Sep 27, 2014 | 2.53B | 38.42M | 1.54% |
| Sep 28, 2013 | 2.49B | 489.63M | 24.45% |
| Sep 29, 2012 | 2.00B | 213.30M | 11.92% |
| Sep 24, 2011 | 1.79B | 109.80M | 6.54% |
| Sep 25, 2010 | 1.68B | 42.42M | 2.59% |
| Sep 26, 2009 | 1.64B | -37.37M | -2.23% |
| Sep 27, 2008 | 1.67B | 936.13M | 126.78% |
| Sep 29, 2007 | 738.37M | 275.69M | 59.59% |
| Sep 30, 2006 | 462.68M | 175.00M | 60.83% |
| Sep 24, 2005 | 287.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
Hologic News
- 1 day ago - HOLX's Genius AI Mammography Flags Missed Breast Cancer Cases - Nasdaq
- 1 day ago - Why Hologic (HOLX) is a Top Momentum Stock for the Long-Term - Nasdaq
- 2 days ago - Hologic's AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams - Business Wire
- 6 days ago - What Is Driving Hologic's Strength in the US Diagnostics Market? - Nasdaq
- 10 days ago - HOLX Stock Up 16% in 6 Months: Is it Still a Hold Heading Into 2026? - Nasdaq
- 10 days ago - How Is The Market Feeling About Hologic Inc? - Benzinga
- 14 days ago - Hologic's BCI Test Shows Growing Impact in Endocrine Therapy Decisions - Nasdaq
- 16 days ago - PSP, Oaktree Among Direct Lenders Buying $2 Billion Hologic Debt3 - Financial Post